Potential targets on Sanofi’s radar
09/09/20 -"In line with its strategy of expanding its focus on the immuno-oncology space and strengthening its internal R&D pipeline, Sanofi has spent €5.2bn on the acquisition of two small biotech firms ..."
Pages
67
Language
English
Published on
09/09/20
You may also be interested by these reports :
30/07/26
Ipsen demonstrated robust performance in Q2, exceeding market expectations, which led to an upgraded 2026 guidance. While we may adjust our estimates ...
30/07/26
Bachem released its 1H26 results on 30 July 2026, delivering a strong operating performance for the half. Margins were affected by higher operating ...
29/07/26
The Q2 profitability was somewhat ahead of consensus, and the firm maintained its full-year guidance. Improving profitability and free cash flows, ...
28/07/26
The Q2 results were ahead of expectations, backed by strong growth across GSK’s key focus areas. The management maintained its full-year guidance. ...